{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T01:16:08Z","timestamp":1774142168932,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12325-025-03400-7","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:08:28Z","timestamp":1761984508000},"page":"5869-5878","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Living with Eosinophilic Granulomatosis with Polyangiitis (EGPA): Podcast of a Patient-Physician Discussion"],"prefix":"10.1007","volume":"42","author":[{"given":"Autumn","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"key":"3400_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejim.2024.06.008","volume":"128","author":"R Solans-Laque","year":"2024","unstructured":"Solans-Laque R, Rua-Figueroa I, Blanco Aparicio M, et al. Red flags for clinical suspicion of eosinophilic granulomatosis with polyangiitis (EGPA). Eur J Intern Med. 2024;128:45\u201352. https:\/\/doi.org\/10.1016\/j.ejim.2024.06.008.","journal-title":"Eur J Intern Med"},{"issue":"2","key":"3400_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/1744666X.2024.2423700","volume":"21","author":"I Rua-Figueroa","year":"2024","unstructured":"Rua-Figueroa I, Solans-Laque R, Blanco-Aparicio M, et al. Ten clinical conundrums in the management of eosinophilic granulomatosis with polyangiitis. Expert Rev Clin Immunol. 2024;21(2):153\u201367. https:\/\/doi.org\/10.1080\/1744666X.2024.2423700.","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"3400_CR3","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.jaci.2023.03.011","volume":"151","author":"ME Wechsler","year":"2023","unstructured":"Wechsler ME, Hellmich B, Cid MC, et al. Unmet needs and evidence gaps in hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol. 2023;151(6):1415\u201328. https:\/\/doi.org\/10.1016\/j.jaci.2023.03.011.","journal-title":"J Allergy Clin Immunol"},{"key":"3400_CR4","unstructured":"Ahmed OS, Matthew SD. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss Syndrome). 2025 [cited 18 March 2025]. https:\/\/emedicine.medscape.com\/article\/333492-overview?form=fpf."},{"issue":"6","key":"3400_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41584-023-00958-w","volume":"19","author":"G Emmi","year":"2023","unstructured":"Emmi G, Bettiol A, Gelain E, et al. Evidence-based guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol. 2023;19(6):378\u201393. https:\/\/doi.org\/10.1038\/s41584-023-00958-w.","journal-title":"Nat Rev Rheumatol"},{"key":"3400_CR6","unstructured":"Vasculitis Foundation. About eosinophilic granulomatosis with polyangiitis. 2024 [cited 18 March 2025]. https:\/\/vasculitisfoundation.org\/education\/vasculitis-types\/eosinophilic-granulomatosis-with-polyangiitis\/."},{"issue":"suppl 9","key":"3400_CR7","first-page":"Abstract 1548","volume":"75","author":"P Dolin","year":"2023","unstructured":"Dolin P, Kielar D, Shavit A, et al. Diagnosis pathways in patients with eosinophilic granulomatosis with polyangiitis (EGPA): a retrospective analysis of US Health Insurance Claims Data [abstract]. Arthritis Rheumatol, 2023;75(suppl 9):Abstract 1548.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"3400_CR8","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/acr.22686","volume":"68","author":"CA Durel","year":"2016","unstructured":"Durel CA, Berthiller J, Caboni S, et al. Long-term followup of a multicenter cohort of 101 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Arthritis Care Res (Hoboken). 2016;68(3):374\u201387. https:\/\/doi.org\/10.1002\/acr.22686.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3400_CR9","first-page":"A249","volume":"79","author":"S Siddiqui","year":"2024","unstructured":"Siddiqui S, Dolin P, Shavit A, et al. The diagnostic journey of patients with eosinophilic granulomatosis with polyangiitis (EGPA) in England: a retrospective observational cohort study. Thorax. 2024;79:A249.","journal-title":"Thorax"},{"issue":"suppl 9","key":"3400_CR10","volume":"70","author":"A Sreih","year":"2018","unstructured":"Sreih A, Shaw D, Young K, et al. Current diagnostic delays in vasculitis and factors associated with time to diagnosis [abstract]. Arthritis Rheumatol. 2018;70(suppl 9):Abs 817.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"3400_CR11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00296-009-1275-y","volume":"31","author":"J Vinit","year":"2011","unstructured":"Vinit J, Muller G, Bielefeld P, et al. Churg-strauss syndrome: retrospective study in Burgundian population in France in past 10 years. Rheumatol Int. 2011;31(5):587\u201393. https:\/\/doi.org\/10.1007\/s00296-009-1275-y.","journal-title":"Rheumatol Int"},{"issue":"4","key":"3400_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/00004836-200110000-00006","volume":"33","author":"AL Buchman","year":"2001","unstructured":"Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol. 2001;33(4):289\u201394. https:\/\/doi.org\/10.1097\/00004836-200110000-00006.","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"3400_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-9-30","volume":"9","author":"D Liu","year":"2013","unstructured":"Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30. https:\/\/doi.org\/10.1186\/1710-1492-9-30.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"11","key":"3400_CR14","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","volume":"39","author":"JB Rice","year":"2017","unstructured":"Rice JB, White AG, Scarpati LM, et al. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017;39(11):2216\u201329. https:\/\/doi.org\/10.1016\/j.clinthera.2017.09.011.","journal-title":"Clin Ther"},{"issue":"10","key":"3400_CR15","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.4065\/81.10.1361","volume":"81","author":"TP Warrington","year":"2006","unstructured":"Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006;81(10):1361\u20137. https:\/\/doi.org\/10.4065\/81.10.1361.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"3400_CR16","first-page":"40","volume":"suppl 103","author":"L Benarous","year":"2017","unstructured":"Benarous L, Terrier B, Laborde-Casterot H, et al. Employment, work disability and quality of life in patients with ANCA-associated vasculitides. The EXPOVAS study. Clin Exp Rheumatol. 2017;35 (suppl 103):40\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"3400_CR17","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1007\/s10067-020-05398-5","volume":"40","author":"N Gill","year":"2021","unstructured":"Gill N, Tervaert JWC, Yacyshyn E. Vasculitis patient journey: a scoping review of patient experiences with vasculitis. Clin Rheumatol. 2021;40(5):1697\u2013708. https:\/\/doi.org\/10.1007\/s10067-020-05398-5.","journal-title":"Clin Rheumatol"},{"key":"3400_CR18","first-page":"1958","volume":"83","author":"J Rowell","year":"2024","unstructured":"Rowell J, Lucas S, Dolin P. AB1239\u2005Measuring the humanistic burden of EGPA: a systematic review. Ann Rheum Dis. 2024;83:1958\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3400_CR19","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s10067-013-2169-7","volume":"32","author":"B Sokolowska","year":"2013","unstructured":"Sokolowska B, Szczeklik W, Pilat O, et al. The impact of current health-related quality of life on future health outlook in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Clin Rheumatol. 2013;32(6):779\u201385. https:\/\/doi.org\/10.1007\/s10067-013-2169-7.","journal-title":"Clin Rheumatol"},{"key":"3400_CR20","doi-asserted-by":"publisher","DOI":"10.1177\/23743735221143953","volume":"9","author":"MJ Strobel","year":"2022","unstructured":"Strobel MJ, Alves D, Roufosse F, et al. Insights from social media on the patient experience of living with rare eosinophil-driven diseases. J Patient Exp. 2022;9:23743735221143953. https:\/\/doi.org\/10.1177\/23743735221143953.","journal-title":"J Patient Exp"},{"issue":"suppl 10","key":"3400_CR21","first-page":"Abstract 1663","volume":"71","author":"G Tomasson","year":"2019","unstructured":"Tomasson G, Pagnoux C, Cuthbertson D, et al. Assessments of quality of life in patients with eosinophilic granulomatosis with polyangiitis [abstract]. Arthritis Rheumatol. 2019;71(suppl 10):Abstract 1663.","journal-title":"Arthritis Rheumatol"},{"key":"3400_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2023.100460","volume":"20","author":"C van Eeden","year":"2023","unstructured":"van Eeden C, Mohazab N, Redmond D, et al. Myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS) and fibromyalgia: PR3-versus MPO-ANCA-associated vasculitis, an exploratory cross-sectional study. Lancet Reg Health. 2023;20:100460. https:\/\/doi.org\/10.1016\/j.lana.2023.100460.","journal-title":"Lancet Reg Health"},{"issue":"8","key":"3400_CR23","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.41773","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021;73(8):1366\u201383. https:\/\/doi.org\/10.1002\/art.41773.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"3400_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","volume":"83","author":"B Hellmich","year":"2024","unstructured":"Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024;83(1):30\u201347. https:\/\/doi.org\/10.1136\/ard-2022-223764.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3400_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.trim.2006.09.018","volume":"17","author":"MM Lopez","year":"2006","unstructured":"Lopez MM, Valenzuela JE, Alvarez FC, et al. Long-term problems related to immunosuppression. Transpl Immunol. 2006;17(1):31\u20135. https:\/\/doi.org\/10.1016\/j.trim.2006.09.018.","journal-title":"Transpl Immunol"},{"issue":"6","key":"3400_CR26","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1097\/LVT.0000000000000341","volume":"30","author":"MW Russo","year":"2024","unstructured":"Russo MW, Wheless W, Vrochides D. Management of long-term complications from immunosuppression. Liver Transpl. 2024;30(6):647\u201358. https:\/\/doi.org\/10.1097\/LVT.0000000000000341.","journal-title":"Liver Transpl"},{"issue":"3","key":"3400_CR27","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.rdc.2023.03.006","volume":"49","author":"JL Bloom","year":"2023","unstructured":"Bloom JL, Langford CA, Wechsler ME. Therapeutic advances in eosinophilic granulomatosis with polyangiitis. Rheum Dis Clin North Am. 2023;49(3):563\u201384. https:\/\/doi.org\/10.1016\/j.rdc.2023.03.006.","journal-title":"Rheum Dis Clin North Am"},{"key":"3400_CR28","unstructured":"FDA. Benralizumab prescribing information. 2024 [cited 6 August 2025]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761070s021lbl.pdf."},{"issue":"20","key":"3400_CR29","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1702079.","journal-title":"N Engl J Med"},{"issue":"10","key":"3400_CR30","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2311155","volume":"390","author":"ME Wechsler","year":"2024","unstructured":"Wechsler ME, Nair P, Terrier B, et al. Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2024;390(10):911\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2311155.","journal-title":"N Engl J Med"},{"issue":"7","key":"3400_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010834.pub4","volume":"7","author":"HA Farne","year":"2022","unstructured":"Farne HA, Wilson A, Milan S, et al. Anti-IL-5 therapies for asthma. Cochrane Database Syst Rev. 2022;7(7):CD010834. https:\/\/doi.org\/10.1002\/14651858.CD010834.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"3400_CR32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12890-024-02885-2","volume":"24","author":"W Li","year":"2024","unstructured":"Li W, Tang SC, Jin L. Adverse events of anti-IL-5 drugs in patients with eosinophilic asthma: a meta-analysis of randomized controlled trials and real-world evidence-based assessments. BMC Pulm Med. 2024;24(1):70. https:\/\/doi.org\/10.1186\/s12890-024-02885-2.","journal-title":"BMC Pulm Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03400-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03400-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03400-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:04:02Z","timestamp":1763132642000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03400-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3400"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03400-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Michael E Wechsler has received consulting, advisory or speaking honoraria from the following: Amgen, Areteia Therapeutics, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Celldex, Cellergy Pharma, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GlaxoSmithKline, Incyte, Kinaset, Merck, Novartis, Om Pharma, Overtone Therapeutics\/Foresite Labs, Phylaxis, Pulmatrix, Rapt Therapeutics, Regeneron, Restorbio, Roche\/Genentech, Sanofi\/Genzyme, Sentien, Sound Biologics, Tetherex Pharmaceuticals, Teva, Upstream Bio and Verona Pharma. Autumn Smith has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This podcast of a patient-physician discussion does not require any ethical approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}